{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Arm", "query": { "intervention": "Placebo Arm" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 5210, "total_pages": 521, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Arm&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T15:30:19.268Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00679432", "title": "(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Blood sampling, endoscopy", "type": "PROCEDURE" }, { "name": "budesonide-MMX® 6 mg", "type": "DRUG" }, { "name": "budesonide-MMX® 9 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asacol® 400 mg", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 510, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 76, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sylacauga", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00679432" }, { "nct_id": "NCT03904498", "title": "COMT Inhibition Among Individuals With Comorbid AUD/ADHD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Use Disorder", "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "Tolcapone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2021-08-16", "completion_date": "2026-03-09", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03904498" }, { "nct_id": "NCT00246532", "title": "Opiate-Induced Tolerance & Hyperalgesia in Pain Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Low Back Pain", "Opioid-induced Hyperalgesia" ], "interventions": [ { "name": "Morphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of General Medical Sciences (NIGMS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 139, "start_date": "2005-10", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2012-04-30", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00246532" }, { "nct_id": "NCT07285798", "title": "A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritability Associated With Autism Spectrum Disorder" ], "interventions": [ { "name": "KarXT", "type": "DRUG" }, { "name": "KarX-EC", "type": "DRUG" }, { "name": "KarXT + KarX-EC Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "5 Years to 17 Years" }, "enrollment_count": 176, "start_date": "2026-09-11", "completion_date": "2029-08-06", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285798" }, { "nct_id": "NCT04505904", "title": "Oxytocin and Approach-avoid in Grief", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prolonged Grief Disorder", "Bereavement" ], "interventions": [ { "name": "Syntocinon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 44, "start_date": "2015-03-20", "completion_date": "2017-05-12", "has_results": true, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505904" }, { "nct_id": "NCT02928978", "title": "Ruxolitinib for Premalignant Breast Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ductal Carcinoma In Situ", "Atypical Lobular Hyperplasia", "Atypical Ductal Hyperplasia", "Lobular Carcinoma In Situ" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Placebo (for Ruxolitinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Julie Nangia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2018-05-13", "completion_date": "2024-09-18", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Indianapolis, Indiana • The Bronx, New York + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02928978" }, { "nct_id": "NCT07022678", "title": "Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia", "Recurrent Acute Myeloid Leukemia" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Xylitol-containing Oral Wipe", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 556, "start_date": "2026-05-26", "completion_date": "2033-01-15", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Madera, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Madera", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07022678" }, { "nct_id": "NCT00890643", "title": "Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "prazosin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Department of Veterans Affairs", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2009-12", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2013-09-23", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890643" }, { "nct_id": "NCT04239014", "title": "A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Placebo to match olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 0, "start_date": "2020-08-07", "completion_date": "2021-01-25", "has_results": false, "last_update_posted_date": "2021-03-10", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 22, "location_summary": "Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "La Jolla", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04239014" }, { "nct_id": "NCT00547014", "title": "First Safety Study in Humans of a Single Dose of CPG 52364", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Placebo Comparator: Cohort 1 Placebo", "type": "DRUG" }, { "name": "52364 3 mg", "type": "DRUG" }, { "name": "Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo", "type": "DRUG" }, { "name": "52364 10 mg", "type": "DRUG" }, { "name": "52364 30 mg", "type": "DRUG" }, { "name": "52364 100 mg", "type": "DRUG" }, { "name": "52364 1 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2007-09", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2009-03-19", "last_synced_at": "2026-09-03T15:30:19.268Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00547014" } ] }